Daiichi Sankyo moves into new UK HQ in Uxbridge Business Park

·         Daiichi Sankyo moves into new UK headquarters in Uxbridge Business park, with its new offices operational from 1 September 2020

·         Move marks significant investment by Japanese pharmaceutical company into the UK as it seeks to continue to expand its presence domestically

Uxbridge, Tuesday 1^st September 2020 – Daiichi Sankyo is today pleased to announce that it has formally relocated its UK headquarters to Uxbridge Business Park, marking a significant investment from the Japanese affiliate company.

Daiichi Sankyo had previously been located at Chalfont Park in Gerrards Cross, leasing office space from June 2006 until this year. To support the ambitions to grow the organisation’s presence in the UK, Daiichi Sankyo announced in early 2020 that it would be relocating its Head Office operations. From today that move is operational, with Head Office staff now working from these new offices permanently.

Daiichi Sankyo’s new Head Office is located in Building 4 of the Business Park, where the company has taken out a 10-year lease on office space fitted with a tailored specification according to the organisation’s needs. Uxbridge Business Park is renowned for its provision of green space and tranquil surroundings. Daiichi Sankyo’s UK footprint has grown substantially in recent years, with more than 200 staff (~70 per cent field force) now working for the company.

Manuel Reiberg, Managing Director of Daiichi Sankyo UK, commented:

“I am really excited about the impact that this relocation will have on our business. In designing the specification for our new corporate offices, we have worked to ensure that they are equipped to spur creativity, productivity and inclusive working environments for all of our staff.

We have taken a consultative approach and invited colleagues to provide feedback. We really want to facilitate innovative and collaborative mind-sets, alongside prioritising the health and wellbeing of our staff.

The safety of our colleagues remain paramount and we are exploring phased-approaches for staff to return to office-based working. Our approach is closely aligned with evolving government guidance for businesses on COVID19.  

As we continue to develop our cardiovascular portfolio, and begin to move into other therapeutic areas such as oncology, I am confident that these new surroundings will help to future-proof our organisation’s growth and allow us to deliver on our commitment to improve patients’ lives.”

James Raven, Arlington’s Chief Executive Officer, said:

“The Arlington team are delighted to welcome Daiichi Sankyo to Uxbridge Business Park.  The continued investment we have made at the Park, together with its exceptional setting and space, has made it one of the best amenetised and most accessible locations from which to conduct business, especially in a post-Covid world. 

We are excited to see the continued growth in the ever important Life Sciences sector, and Daiichi Sankyo’s commitment to the Park emphasises the importance of the growing cluster we have at Uxbridge Business Park. We very much look forward to a long and successful partnership together.”